{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:14:50Z","timestamp":1773162890038,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010479","name":"Cook Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00270-018-2110-1","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T14:11:04Z","timestamp":1541686264000},"page":"358-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results"],"prefix":"10.1007","volume":"42","author":[{"given":"Kimihiko","family":"Kichikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-4079","authenticated-orcid":false,"given":"Shigeo","family":"Ichihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiro","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Nanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin E.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron E.","family":"Lottes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott A.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Dake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"issue":"3","key":"2110_CR1","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jvs.2009.04.019","volume":"50","author":"DD Dearing","year":"2009","unstructured":"Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz SG. Primary stenting of the superficial femoral and popliteal artery. J Vasc Surg. 2009;50(3):542\u20137. \n                    https:\/\/doi.org\/10.1016\/j.jvs.2009.04.019\n                    \n                  .","journal-title":"J Vasc Surg"},{"issue":"7","key":"2110_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jcin.2014.01.168","volume":"7","author":"O Iida","year":"2014","unstructured":"Iida O, Takahara M, Soga Y, Suzuki K, Hirano K, Kawasaki D, et al. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery. J Am Coll Cardiol Interv. 2014;7(7):792\u20138. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2014.01.168\n                    \n                  .","journal-title":"J Am Coll Cardiol Interv"},{"issue":"6","key":"2110_CR3","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jvs.2016.05.073","volume":"64","author":"K Stavroulakis","year":"2016","unstructured":"Stavroulakis K, Torsello G, Manal A, Schwindt A, Hericks C, Stachmann A, et al. Results of primary stent therapy for femoropopliteal peripheral arterial disease at 7 years. J Vasc Surg. 2016;64(6):1696\u2013702. \n                    https:\/\/doi.org\/10.1016\/j.jvs.2016.05.073\n                    \n                  .","journal-title":"J Vasc Surg"},{"issue":"3","key":"2110_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jcin.2015.09.035","volume":"9","author":"H Yokoi","year":"2016","unstructured":"Yokoi H, Ohki T, Kichikawa K, Nakamura M, Komori K, Nanto S, et al. Zilver PTX post-market surveillance study of paclitaxel-eluting stents for treating femoropopliteal artery disease in Japan: 12-month results. J Am Coll Cardiol Interv. 2016;9(3):271\u20137. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2015.09.035\n                    \n                  .","journal-title":"J Am Coll Cardiol Interv"},{"issue":"5","key":"2110_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCINTERVENTIONS.111.962324","volume":"4","author":"MD Dake","year":"2011","unstructured":"Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5):495\u2013504. \n                    https:\/\/doi.org\/10.1161\/circinterventions.111.962324\n                    \n                  .","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"2110_CR6","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1583\/11-3560.1","volume":"18","author":"MD Dake","year":"2011","unstructured":"Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18(5):613\u201323. \n                    https:\/\/doi.org\/10.1583\/11-3560.1\n                    \n                  .","journal-title":"J Endovasc Ther"},{"issue":"15","key":"2110_CR7","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.115.016900","volume":"133","author":"MD Dake","year":"2016","unstructured":"Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX Randomized Trial. Circulation. 2016;133(15):1472\u201383. \n                    https:\/\/doi.org\/10.1161\/circulationaha.115.016900\n                    \n                  .","journal-title":"Circulation"},{"issue":"8","key":"2110_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jcin.2015.03.022","volume":"8","author":"O Iida","year":"2015","unstructured":"Iida O, Takahara M, Soga Y, Nakano M, Yamauchi Y, Zen K, et al. 1-year results of the ZEPHYR registry (Zilver PTX for the femoral artery and proximal popliteal artery): predictors of restenosis. J Am Coll Cardiol Interv. 2015;8(8):1105\u201312. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2015.03.022\n                    \n                  .","journal-title":"J Am Coll Cardiol Interv"},{"issue":"1","key":"2110_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jvir.2017.08.014","volume":"29","author":"S Cipollari","year":"2018","unstructured":"Cipollari S, Yokoi H, Ohki T, Kichikawa K, Nakamura M, Komori K, et al. Long-term effectiveness of the Zilver PTX drug-eluting stent for femoropopliteal peripheral artery disease in patients with no patent tibial runoff vessels\u2014results from the Zilver PTX Japan post-market surveillance study. J Vasc Interv Radiol. 2018;29(1):9\u201317.e1. \n                    https:\/\/doi.org\/10.1016\/j.jvir.2017.08.014\n                    \n                  .","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"2110_CR10","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00270-017-1673-6","volume":"40","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, Yokoi H, Ohki T, Kichikawa K, Nakamura M, Komori K, et al. Impact of chronic renal failure on safety and effectiveness of paclitaxel-eluting stents for femoropopliteal artery disease: subgroup analysis from Zilver PTX post-market surveillance study in Japan. Cardiovasc Intervent Radiol. 2017;40(11):1669\u201377. \n                    https:\/\/doi.org\/10.1007\/s00270-017-1673-6\n                    \n                  .","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"2110_CR11","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.jvir.2016.05.042","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Takahara M, Shintani Y, Tanaka A, Soga Y, Yamaoka T, et al. Retrospective multicenter comparison of S.M.A.R.T. CONTROL and MISAGO stents in treatment of femoropopliteal lesions. J Vasc Interv Radiol. 2016;27(11):1642\u20139. \n                    https:\/\/doi.org\/10.1016\/j.jvir.2016.05.042\n                    \n                  .","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"2110_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1253\/circj.CJ-13-1147","volume":"78","author":"H Aihara","year":"2014","unstructured":"Aihara H, Soga Y, Mii S, Okazaki J, Yamaoka T, Kamoi D, et al. Comparison of long-term outcome after endovascular therapy versus bypass surgery in claudication patients with Trans-Atlantic Inter-Society Consensus-II C and D femoropopliteal disease. Circ J. 2014;78(2):457\u201364.","journal-title":"Circ J"},{"issue":"7","key":"2110_CR13","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1253\/circj.CJ-12-1538","volume":"77","author":"T Ishihara","year":"2013","unstructured":"Ishihara T, Iida O, Awata M, Fujita M, Watanabe T, Ishida Y, et al. Two-month angioscopic evaluation of superficial femoral artery treated with paclitaxel-coated nitinol drug-eluting stent. Circ J. 2013;77(7):1880\u20132.","journal-title":"Circ J"},{"issue":"1","key":"2110_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12928-014-0287-z","volume":"30","author":"T Ishihara","year":"2015","unstructured":"Ishihara T, Iida O, Awata M, Nanto K, Shiraki T, Okamoto S, et al. Extensive arterial repair one year after paclitaxel-coated nitinol drug-eluting stent vs. bare-metal stent implantation in the superficial femoral artery. Cardiovasc Intervent Ther. 2015;30(1):51\u20136. \n                    https:\/\/doi.org\/10.1007\/s12928-014-0287-z\n                    \n                  .","journal-title":"Cardiovasc Intervent Ther"},{"issue":"2","key":"2110_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jvs.2015.08.093","volume":"63","author":"T Ohki","year":"2016","unstructured":"Ohki T, Angle JF, Yokoi H, Jaff MR, Popma J, Piegari G, et al. One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study). J Vasc Surg. 2016;63(2):370\u2013376.e1. \n                    https:\/\/doi.org\/10.1016\/j.jvs.2015.08.093\n                    \n                  .","journal-title":"J Vasc Surg"},{"issue":"1","key":"2110_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jvs.2017.01.065","volume":"66","author":"T Ohki","year":"2017","unstructured":"Ohki T, Kichikawa K, Yokoi H, Uematsu M, Yamaoka T, Maeda K, et al. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg. 2017;66(1):130\u2013142.e1. \n                    https:\/\/doi.org\/10.1016\/j.jvs.2017.01.065\n                    \n                  .","journal-title":"J Vasc Surg"},{"issue":"2","key":"2110_CR17","doi-asserted-by":"publisher","first-page":"e002730","DOI":"10.1161\/CIRCINTERVENTIONS.115.002730","volume":"9","author":"S Banerjee","year":"2016","unstructured":"Banerjee S, Sarode K, Mohammad A, Gigliotti O, Baig MS, Tsai S, et al. Femoropopliteal artery stent thrombosis: report from the excellence in peripheral artery disease registry. Circ Cardiovasc Interv. 2016;9(2):e002730. \n                    https:\/\/doi.org\/10.1161\/circinterventions.115.002730\n                    \n                  .","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"2110_CR18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1583\/14-4753.1","volume":"21","author":"T Ohki","year":"2014","unstructured":"Ohki T, Yokoi H, Kichikawa K, Kimura T, Snyder SA, Ragheb AO, et al. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials. J Endovasc Ther. 2014;21(5):644\u201353. \n                    https:\/\/doi.org\/10.1583\/14-4753.1\n                    \n                  .","journal-title":"J Endovasc Ther"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00270-018-2110-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-018-2110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-018-2110-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T19:29:40Z","timestamp":1573154980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00270-018-2110-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1007\/s00270-018-2110-1","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"28 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Kichikawa has received speakers\u2019 fees from Cook Medical. Dr. Yokoi has received speakers\u2019 fees from Cook Medical. Dr. Ohki has received research fees for clinical trials. Drs.\u00a0O\u2019Leary, Lottes, Snyder are paid employees of Cook Research Incorporated., a contract research organization and Cook Group Company. Dr. Dake is a member of the scientific advisory board for W.L. Gore and Associates and has received consulting fees from Cook Medical and Novate Medical. All other authors have reported that they have no conflicts relevant to the contents of this paper to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For this type of study, informed consent processes were determined by each institution\u2019s ethical committee policy to specify whether informed consent was necessary or outcome data could be abstracted while protecting patient\u2019s rights without requiring individual patient consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}